-
The E1910 study was a multinational, randomized, controlled, phase 3 trial of BLINCYTO® alternating with chemotherapy vs chemotherapy alone in frontline consolidation in 224 newly diagnosed patients aged 30–70 years with Ph(–) B-cell precursor ALL. OS was calculated from time of randomization until death due to any cause1,2
- Primary endpoint was 3-year KM estimates for OS: 84.8% in the BLINCYTO® arm (n=112) vs 69.0% in the chemotherapy only arm (n=112); HR: 0.42 (95% CI: 0.24–0.75);* P = 0.003 (the stratified log-rank test). Median follow-up was 3.6 years in both arms1
- 5-year KM estimates for OS: 82.4% in the BLINCYTO® arm (n=112) vs 62.5% in the chemotherapy only arm (n=112); HR: 0.44 (95% CI: 0.25–0.76)1,†
- Additionally, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend blinatumomab as part of the ECOG1910 regimen, a preferred frontline treatment regimen for adult patients with Ph(–) B-cell precursor ALL3